psalexa
logo

Hereditary Angioedema (HAE) Therapeutics

Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS10974
Available Format:
Pages: 105

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.3 Key Barriers

4.4 Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis by Phase (2017)

5.1 Phase III: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase II: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Phase I: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Clinical Trials

5.3.4 Clinical Results

5.3.5 Strategic Development

5.3.6 Designation

5.3.7 Grants

5.3.8 Patent

5.3.9 Technology

5.4 Pre-Clinical: Drug profiles

5.4.1 Pre-Clinical Study

5.4.2 Pre-Clinical Results

5.4.3 Strategic Development

5.4.4 Designation

5.4.5 Grants

5.4.6 Patent

5.4.7 Technology

5.5 Discovery: Drug profiles

5.5.1 Strategic Development

5.5.2 Designation

5.5.3 Grants

5.5.4 Patent

5.5.5 Technology

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Hereditary Angioedema (HAE) Therapeutics Pipeline

7.2 SWOT Analysis of Hereditary Angioedema (HAE) Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Pipeline Products

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

 

PIPELINE ANALYSIS OF HEREDITARY ANGIOEDEMA (HAE) THERAPEUTICS, BY COMPANY (2017)

DESCRIPTION OF PHASE III DRUG CANDIDATES

CLINICAL TRIALS OF PHASE III DRUG CANDIDATES

DESCRIPTION OF PHASE II DRUG CANDIDATES

CLINICAL TRIALS OF PHASE II DRUG CANDIDATES

DESCRIPTION OF PHASE I DRUG CANDIDATES

CLINICAL TRIALS OF PHASE I DRUG CANDIDATES

DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES

DESCRIPTION OF DISCOVERY DRUG CANDIDATES

COMPANIES - AT A GLANCE

 

LIST OF FIGURES

RESEARCH METHODOLOGY

SPLIT OF PRIMARY AND SECONDARY RESEARCH

BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

HAE THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

HAE THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

HAE THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

BREAKDOWN OF CLINICAL TRIALS, BY REGION

BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

KEY PLAYERS BENCHMARKING

SWOT ANALYSIS

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry